By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Adamas Pharmaceuticals 

1900 Powell Street
Suite 1050
Emeryville  California  94608  U.S.A.
Phone: 510-450-3500 Fax: 510-428-0519


SEARCH JOBS


Industry
Pharmaceutical

Segment
Pharmaceuticals





Company News
Adamas Pharmaceuticals (ADMS) Provides Review Of 2014 And Previews Upcoming Business Drivers 1/12/2015 7:18:15 AM
Adamas Pharmaceuticals (ADMS) Receives $30 Million Milestone Payment From Actavis (ACT) 1/9/2015 7:23:19 AM
Actavis (ACT) and Adamas Pharmaceuticals (ADMS) Announce FDA Approval of Namzaric™, a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride 12/24/2014 6:40:53 AM
Actavis (ACT), Adamas Pharmaceuticals (ADMS) Win FDA Approval for Alzheimer's Drug Namzaric 12/24/2014 6:39:42 AM
Adamas Pharmaceuticals (ADMS) Issued Six Additional U.S. Patents 12/4/2014 4:31:36 PM
Adamas Pharmaceuticals (ADMS) To Present At Piper Jaffray Healthcare Conference 11/19/2014 12:45:19 PM
Adamas Pharmaceuticals (ADMS) To Present At 2014 Credit Suisse Healthcare Conference 11/6/2014 8:21:18 AM
Adamas Pharmaceuticals (ADMS) Reports Third Quarter 2014 Financial Results 11/5/2014 7:46:03 AM
Adamas Pharmaceuticals (ADMS) Expands Its Phase 3 Program With ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Patients With Parkinson's Disease 10/29/2014 7:19:28 AM
Adamas Pharmaceuticals (ADMS) Reports Second Quarter 2014 Financial Results 8/8/2014 10:50:57 AM
1234
//-->